SILVER SPRING, Md., Aug. 29, 2011 /PRNewswire-USNewswire/ -- Science, public health, and regulatory highlights from the U.S. Food and Drug Administration. Information in this document is designed for credentialed journalists. Release dates and times for items are current as of August 29, 2011.
(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)
FDA News & Notes does not contain any regulatory or enforcement actions due to legal limitations.
Events and Speeches for the Commissioner and FDA leadership:
Thursday, 9/8 FDA Commissioner Margaret Hamburg, M.D., delivers keynote remarks titled “Reducing Risk Through Effective Policy and Public Health Practice,” at the conference on 9/11 + 10: Science, Policy, and Public Health; Looking Ahead to the Next 10 Years in New York. 10:15 a.m., Columbia University, Low Memorial Library, 535 West 116th Street, New York City.
Columbia University Contacts: Stephanie Berger, sb2247@columbia.edu, 212-305-4372 Claudia Willis, cw2462@columbia.edu, 212-305-8044
Press Office Contact: Raymond Formanek Jr., raymond.formanek@fda.hhs.gov, 301-796-4677
Meetings, Workshops and Congressional Testimony:
Tuesday, 8/30 The General and Plastic Surgery Devices Panel will make recommendations on postmarketing issues related to silicone gel-filled breast implants during a two-day meeting. 8 a.m., Hilton Washington D.C. North/Gaithersburg, 620 Perry Pkwy., Ballroom, Gaithersburg, Md.
Press Office Contact: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov
Thursday, 9/8 The Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee holds a two-day meeting to make recommendations on the safety and effectiveness of transvaginal surgical mesh used for repair of pelvic organ prolapse. 8 a.m., Holiday Inn, 2 Montgomery Village Ave., Ballroom, Gaithersburg, Md.
Press Office Contact: Karen Riley, 301-796-4674, karen.riley@fda.hhs.gov
Friday, 9/9 The Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee discuss the benefits and risks of long-term bisphosphonate use for the treatment and prevention of osteoporosis. 8 a.m., Marriott Inn and Conference Center, University of Maryland University College, 3501 University Blvd. East, Adelphi, Md.
Press Office Contact Jeff Ventura at 301-796-2807, jeffrey.ventura@fda.hhs.gov
On the Web:
Classification of the Eyelid Thermal Pulsation System
Press Office Contact: Karen Riley, 301-796-4674; karen.riley@fda.hhs.gov
FDA Office of Public Affairs Contact Information:
Call or email FDA Office of Public Affairs, 301-796-4540, fdaopa@fda.hhs.gov
List of FDA press officers and beats
More Resources:
FDA News and Events
FDA Photos (Flickr)
Consumer Health Information
SOURCE U.S. Food and Drug Administration
